Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome
Alan F. List(TE Laboratories (Ireland)), Emmanuel C. Besa(UCLA Medical Center), Maria R. Baer(University of Maryland, Baltimore), Noelia Martinez-Lopez(Roswell Park Comprehensive Cancer Center), Jason Esposito(Roswell Park Comprehensive Cancer Center), Azra Raza(University of Illinois Chicago), John Feigert(Roswell Park Comprehensive Cancer Center), David P. Steensma(Harvard University), Carole Paley(Roswell Park Comprehensive Cancer Center)
Cited by 175
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
|Journal of Clinical Oncology|2009|963
Efficacy of Lenalidomide in Myelodysplastic Syndromes
|New England Journal of Medicine|2005|874